I have two quick things to share with you:
Thing #1: Two new insulins coming soon.
One new insulin is called Basaglar. It’s supposed to be a lot like Lantus/Levemir/Tresiba/Toujeo, but it’s going to cost about 75% less than the current long acting analog insulins. So if you have crappy drug coverage, this could be a great option for you. Basaglar should be available in pharmacies mid-December. I haven't tried it yet, so I have no opinion about it's efficacy. Some insurance companies have already replaced their tier 1 long-acting analog with Basaglar on their 2017 formulary, so you might end up taking Basaglar next year whether you want to or not.
The other insulin is called Ryzodeg. It’s a 70/30 mix, meaning it’s 70% Tresiba/Degludec (which is a new long-acting insulin released earlier this year) and 30% apart (which is Novolog). Because Degludec doesn’t have strong peak times, diabetics taking Humalog 75/25, Humulin 70/30, Novolog 70/30 and Novolin 70/30 could consider switching to Ryzodeg. My guess is that Ryzodeg could reduce hypoglycemic events caused by the other mixes as long as you’re using the correct dose. I have contacted Novo Nordisk for the date on which Ryzodeg will be available in U.S. Pharmacies and will update my blog when this information becomes available.
Thing #2: Here's an article on the dismal state of 2017 prescription formularies.
The short version is: check your insurance company's 2017 formulary. A bunch of drugs are getting cut, and you need to have a plan to ensure you don't have a break in drug coverage. This may mean calling your doctor and getting a new script for a new (biosimilar) drug just before January.